KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.

Rachel Chihana, Jia Jin Kee, Zoe Moodie, Yunda Huang, Holly Janes, Sufia Dadabhai, Alison C Roxby, Mary Allen, Sheetal Kassim, Vimla Naicker, Craig Innes, Nivashnee Naicker, Thozama Dubula, Nicole Grunenberg, Mookho Malahleha, James G Kublin, Linda-Gail Bekker, Glenda Gray, Johnstone Kumwenda, Fatima Laher

Vaccine 42(20) 125991

PMID38772835
PMCIDPMC11320363
DOI10.1016/j.vaccine.2024.05.039
发表日期2024-05-21
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Reactogenicity informs vaccine safety, and may influence vaccine uptake. We evaluated factors associated with reactogenicity in HVTN 702, a typical HIV vaccine efficacy trial with multiple doses and products. METHODS: HVTN 702, a phase 2b/3 double-blind placebo-controlled trial, randomized 5404 African participants aged 18-35 years without HIV to placebo, or ALVAC-HIV (vCP2438) at months 0, 1 and ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, 12 and 18. Using multivariate logistic regression, we evaluated associations between reactogenicity with clinical, sociodemographic and laboratory variables. RESULTS: More vaccine than placebo-recipients reported local symptoms (all p < 0.001), arthralgia (p = 0.008), chills (p = 0.012) and myalgia (p < 0.001). Reactogenicity was associated with female sex at birth (ORv = 2.50, ORp = 1.81, both p < 0.001) and geographic region. Amongst vaccine-recipients, each year of age was associated with 3 % increase in reactogenicity (OR = 1.03, p = 0.002). CONCLUSION: Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。